Probi Defendum®


Probi Defendum® is based on a combination of the probiotic strains Lactiplantibacillus plantarum HEAL9 (HEAL9™) and Lacticaseibacillus paracasei 8700:2 (L. paracasei 8700:2™), equally contributing to the clinically documented dose of 1 billion (1 B) CFU per day. Several studies describe immune effects after intake of Probi Defendum® with findings on endpoints such as decreased incidence of the common cold, decreased duration of common cold episodes, and decreased severity of common cold measures. The strain L. paracasei 8700:2 has also been studied separately for effects on immune cells and shown to increase the population of natural killer T (NKT) cells and promote phagocytosis.

Probi Defendum® is a registered trademark of Probi AB.

Watch the probiotic mode of action of Probi Defendum®:

Scientific reference(s)

Berggren, A., et al., Randomised, double-blind and placebo-controlled study using new probiotic lactobacilli for strengthening the body immune defence against viral infections. Eur J Nutr, 2011. 50(3): p. 203-10.

Busch, R., J. Gruenwald, and S. Dudek, Randomized, double blind and placebo controlled study using a combination of two probiotic lactobacilli to alleviate symptoms and frequency of common cold. Food and Nutrition
Sciences, 2013. 4: p. 13-20.

Lazou Ahren, I., et al., Evaluation of the efficacy of Lactobacillus plantarum HEAL9 and Lactobacillus paracasei 8700:2 on aspects of common cold infections in children attending day care: a randomised, double-blind, placebo-controlled clinical study. Eur J Nutr, 2020. 59(1): p. 409-417.

Ahren, I.L., et al., Fewer Community-Acquired Colds with Daily Consumption of Lactiplantibacillus plantarum HEAL9 and Lacticaseibacillus paracasei 8700:2. A Randomized, Placebo-Controlled Clinical Trial. J Nutr, 2021. 151(1): p. 214-222.
Batu E.D., Akca U.K., Basaran O., Bilginer Y., and Özen S (2022). Probiotic use in the prophylaxis of periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome: a retrospective cohort study. Rheumatology International, 42, 1207-1211.

Hütt P, Shchepetova J, Loivukene K, Kullisaar T, Mikelsaar M (2006) Antagonistic activity of probiotic lactobacilli and bifidobacteria against entero- and uropathogens. J Appl
Microbiol 100: 1324-1332.
Lavasani S, Dzhambazov B, Nouri M, Fak F, Buske S, et al. (2010) A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis
mediated by IL-10 producing regulatory T cells. PLoS One 5: e9009.
Humphreys, G. J., & McBain, A. J. (2019). Antagonistic effects of Streptococcus and Lactobacillus probiotics in pharyngeal biofilms. Letters in applied microbiology, 68(4), 303–312.

Additional info

Therapeutical area(s)

Immune system



Adults · Children · Elderly

Dosage form

sachets, capsule, sticks, tablets, multilayer tablets


1 billion(s)
Scroll to Top
Browse companies by type
Brought to you by